VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, these results underscore the potential of VERAXA’s proprietary BiTAC approach, which is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
VERAXA maintains a diversified oncology pipeline of antibody-based formats, including antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and other antibody-based formats. The BiTAC-ADC platform expands on the company’s broader BiTAC technology, which aims to enhance tumor selectivity and reduce off-target toxicity. The company recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.
For more information on VERAXA and its pipeline, visit the company’s newsroom at https://nnw.fm/VRXA.
